FDA approves drug for rare bone condition

June 13, 2013 3:04 PM

4 0

FDA approves drug for rare bone condition

An immune-boosting biologic therapy already used to prevent fractures in patients with bone metastases has won the FDA's approval as a treatment for a rare but painful condition called giant cell tumor of the bone.

The FDA gave an expedited review to Xgeva as an orphan therapy, because its use is expected to benefit a small population of patients. Xgeva is marketed by Thousand Oaks-based Amgen.

Read more

To category page

Loading...